Table 5.
Association between genotypes of MMP9, 2 and 3 and NSCLC patients' survival of CAPUA study
| Genotypes | Patients | Deaths | MST (months) |
Crude HR | 95% CI | HRa | 95% CI |
|---|---|---|---|---|---|---|---|
| MMP9 | n = 625 | ||||||
| C/C | 477 | 447 | 10.1 | 1.00 | 1.00 | ||
| C/T | 144 | 131 | 9.3 | 0.91 | 0.74-1.10 | 1.03 | 0.84-1.26 |
| T/T | 4 | 4 | 12.8 | 1.17 | 0.44-3.13 | 0.85 | 0.32-2.30 |
| MMP2 | n = 668 | ||||||
| C/C | 481 | 446 | 10.0 | 1.00 | 1.00 | ||
| C/T | 174 | 164 | 9.4 | 1.10 | 0.92-1.32 | 1.12 | 0.93-1.35 |
| T/T | 13 | 12 | 10.6 | 1.37 | 0.77-2.44 | 1.79 | 1.00-3.20 |
| MMP3 | n = 593 | ||||||
| 6A/6A | 148 | 137 | 14.1 | 1.00 | 1.00 | ||
| 6A/5A | 300 | 282 | 9.1 | 1.16 | 0.95-1.43 | 0.95 | 0.77-1.18 |
| 5A/5A | 145 | 135 | 9.3 | 1.09 | 0.86-1.39 | 0.92 | 0.72-1.18 |
aAdjusted by age, gender, pack-years, histological type, clinical stage, surgical operation and radio and chemotherapy
MST: median survival time